Applied Clinical Trials Online2d
Doravirine/Islatravir Regimen Shows Promise in Multiple Phase III Trials for the Treatment of HIV
The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change ...
TipRanks on MSN1d
MoonLake Immunotherapeutics Advances Clinical Trials in 2024
Moonlake Immunotherapeutics ( ($MLTX) ) has released its Q4 earnings. Here is a breakdown of the information Moonlake Immunotherapeutics presented ...
Alzamend Neuro announces initiation of Phase II trial of AL001
Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD ...
The Manila Times2d
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
"Receiving the FDA's clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
The Manila Times6d
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
Zhejiang Doer Biologics Co., Ltd. ('Doer Bio'), a clinical stage biopharmaceutical company developing innovative ...
Business Wire9d
Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Trea…
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
Morningstar6d
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia
has completed the enrollment in the Phase 2 clinical study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG) ("DR10624-201 study"). The DR10624-201 study is a randomized ...